LIVIVO - Search results -

Search results

Result 1 - 10 of total 33

Search options

Article ; Online: Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?: A Systematic Review.

Saha, Animesh / Wadsley, Jonathan / Sirohi, Bhawna / Goody, Rebecca / Anthony, Alan / Perumal, Karthikeyan / Ulahanan, Danny / Collinson, Fiona

Pancreas

2023 Volume 52, Issue 1, Page(s) e7–e20

Abstract: Objectives: The role of concomitant chemoradiotherapy or radiotherapy (RT) after induction chemotherapy (IC) in borderline resectable and locally advanced pancreatic ductal adenocarcinoma is debatable. This systematic review aimed to explore this.: ... ...

Abstract	Objectives: The role of concomitant chemoradiotherapy or radiotherapy (RT) after induction chemotherapy (IC) in borderline resectable and locally advanced pancreatic ductal adenocarcinoma is debatable. This systematic review aimed to explore this. Methods: We searched PubMed, MEDLINE, EMBASE, and Cochrane database. Studies were selected reporting outcomes on resection rate, R0 resection, pathological response, radiological response, progression-free survival, overall survival, local control, morbidity, and mortality. Results: The search resulted in 6635 articles. After 2 rounds of screening, 34 publications were selected. We found 3 randomized controlled studies and 1 prospective cohort study, and the rest were retrospective studies. There is consistent evidence that addition of concomitant chemoradiotherapy or RT after IC improves pathological response and local control. There are conflicting results in terms of other outcomes. Conclusions: Concomitant chemoradiotherapy or RT after IC improves local control and pathological response in borderline resectable and locally advanced pancreatic ductal adenocarcinoma. The role of modern RT in improving other outcome requires further research.
MeSH term(s)	Humans ; Retrospective Studies ; Prospective Studies ; Induction Chemotherapy ; Pancreatic Neoplasms/pathology ; Chemoradiotherapy/methods ; Carcinoma, Pancreatic Ductal/pathology ; Neoadjuvant Therapy/methods ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Pancreatic Neoplasms
Language	English
Publishing date	2023-06-01
Publishing country	United States
Document type	Systematic Review ; Journal Article
ZDB-ID	632831-3
ISSN	1536-4828 ; 0885-3177
ISSN (online)	1536-4828
ISSN	0885-3177
DOI	10.1097/MPA.0000000000002215
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2160: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.

Bhaskaran, Divyalakshmi / Savage, Joshua / Patel, Amit / Collinson, Fiona / Mant, Rhys / Boele, Florien / Brazil, Lucy / Meade, Sara / Buckle, Peter / Lax, Siân / Billingham, Lucinda / Short, Susan C

BMC cancer

2024 Volume 24, Issue 1, Page(s) 83

Abstract: Background: Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 per year in England. Patients with tumours showing O: Methods: ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, ...

Abstract	Background: Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 per year in England. Patients with tumours showing O Methods: ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to assess cannabinoids in patients with recurrent MGMT methylated GBM who are suitable for treatment with TMZ. Patients who have relapsed ≥ 3 months after completion of initial first-line treatment will be randomised 2:1 to receive either nabiximols or placebo in combination with TMZ. The primary outcome is overall survival time defined as the time in whole days from the date of randomisation to the date of death from any cause. Secondary outcomes include overall survival at 12 months, progression-free survival time, HRQoL (using patient reported outcomes from QLQ-C30, QLQ-BN20 and EQ-5D-5L questionnaires), and adverse events. Discussion: Patients with recurrent MGMT promoter methylated GBM represent a relatively good prognosis sub-group of patients with GBM. However, their median survival remains poor and, therefore, more effective treatments are needed. The phase II design of this trial was chosen, rather than phase III, due to the lack of data currently available on cannabinoid efficacy in this setting. A randomised, double-blind, placebo-controlled trial will ensure an unbiased robust evaluation of the treatment and will allow potential expansion of recruitment into a phase III trial should the emerging phase II results warrant this development. Trial registration: ISRCTN: 11460478. Clinicaltrials: Gov: NCT05629702.
MeSH term(s)	Adult ; Humans ; Antineoplastic Agents, Alkylating/therapeutic use ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Cannabinoids/therapeutic use ; Clinical Trials, Phase II as Topic ; Glioblastoma/drug therapy ; Glioblastoma/genetics ; Glioblastoma/pathology ; Multicenter Studies as Topic ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Quality of Life ; Randomized Controlled Trials as Topic ; Temozolomide/therapeutic use
Chemical Substances	Antineoplastic Agents, Alkylating ; Cannabinoids ; Temozolomide (YF1K15M17Y)
Language	English
Publishing date	2024-01-15
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-023-11792-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients.

West, Emma J / Scott, Karen J / Tidswell, Emma / Bendjama, Kaidre / Stojkowitz, Nicolas / Lusky, Monika / Kurzawa, Marta / Prasad, Raj / Toogood, Giles / Ralph, Christy / Anthoney, D Alan / Melcher, Alan A / Collinson, Fiona J / Samson, Adel

Cancers

2022 Volume 14, Issue 9

Abstract: ... Pexa- ... ...

Abstract	Pexa-Vec
Language	English
Publishing date	2022-04-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14092181
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The Incidence of Low Anterior Resection Syndrome as Assessed in an International Randomized Controlled Trial (MRC/NIHR ROLARR).

Bolton, William S / Chapman, Stephen J / Corrigan, Neil / Croft, Julie / Collinson, Fiona / Brown, Julia M / Jayne, David G

Annals of surgery

2020 Volume 274, Issue 6, Page(s) e1223–e1229

Abstract: Objective: To investigate the incidence of LARS in patients undergoing elective anterior resection within the MRC/NIHR ROLARR trial and to explore perioperative variables that might be associated with major LARS.: Summary background data: Sphincter- ... ...

Abstract	Objective: To investigate the incidence of LARS in patients undergoing elective anterior resection within the MRC/NIHR ROLARR trial and to explore perioperative variables that might be associated with major LARS. Summary background data: Sphincter-preserving rectal cancer surgery is frequently accompanied by defaecatory dysfunction known as Low anterior resection syndrome (LARS). This is distressing for patients and is an unmet clinical challenge. Methods: An international, retrospective cohort study of patients undergoing anterior resection within the ROLARR trial was undertaken. Trial participants with restoration of gastrointestinal continuity and free from disease recurrence completed the validated LARS questionnaire between August 2015 and April 2017. The primary outcome was the incidence of LARS and secondary outcome was severity (minor versus major). Results: LARS questionnaires were received from 132/155 (85%) eligible patients. The median time from surgery to LARS assessment was 1065 days (range 174-1655 d). The incidence of LARS was 82.6% (n = 109/132), which was minor in 26/132 (19.7%) and major in 83/132 (62.9%). The most common symptoms were incontinence to flatus (n = 86/132; 65.2%) and defaecatory clustering (88/132; 66.7%). In a multivariate model, predictors of major LARS were: 1 cm decrease in tumor height above the anal verge (OR = 1.290, 95% CI: 1.101,1.511); and an ASA grade greater than 1 (OR = 2.920, 95% CI: 1.239, 6.883). Treatment allocation (laparoscopic vs robotic) did not predict major LARS. Conclusions: LARS is a common after rectal cancer surgery and patients should be appropriately counselled preoperatively, particularly before surgery for low tumors or in comorbid populations.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Cross-Sectional Studies ; Female ; Humans ; Incidence ; Laparoscopy ; Male ; Middle Aged ; Postoperative Complications/epidemiology ; Rectal Neoplasms/surgery ; Risk Factors ; Robotic Surgical Procedures ; Surveys and Questionnaires ; Syndrome
Language	English
Publishing date	2020-02-19
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	340-2
ISSN	1528-1140 ; 0003-4932
ISSN (online)	1528-1140
ISSN	0003-4932
DOI	10.1097/SLA.0000000000003806
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.35/1: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer.

Zhong, Jim / Palkhi, Ebrahim / Buckley, David L / Collinson, Fiona J / Ralph, Christy / Jagdev, Satinder / Vasudev, Naveen S / Swain, Jayne / Brown, Janet E / Wah, Tze Min

Diagnostics (Basel, Switzerland)

2021 Volume 11, Issue 7

Abstract: ... ...

Abstract	Objective
Language	English
Publishing date	2021-07-20
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662336-5
ISSN	2075-4418
ISSN	2075-4418
DOI	10.3390/diagnostics11071302
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

Vasudev, Naveen S / Ainsworth, Gemma / Brown, Sarah / Pickering, Lisa / Waddell, Tom / Fife, Kate / Griffiths, Richard / Sharma, Anand / Katona, Eszter / Howard, Helen / Velikova, Galina / Maraveyas, Anthony / Brown, Janet / Pezaro, Carmel / Tuthill, Mark / Boleti, Ekaterini / Bahl, Amit / Szabados, Bernadett / Banks, Rosamonde E /

Brown, Joanne / Venugopal, Balaji / Patel, Poulam / Jain, Ankit / Symeonides, Stefan N / Nathan, Paul / Collinson, Fiona J / Powles, Thomas

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2023 Volume 42, Issue 3, Page(s) 312–323

Abstract: Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether ... ...

Abstract	Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile. Methods: Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the proportion of patients with a grade 3-5 treatment-related adverse event (trAE) among those who received at least one dose of therapy. The key secondary end point was 12-month progression-free survival (PFS) in the modified arm compared with historical sunitinib control. The study was not designed to formally compare arms for efficacy. Results: Between March 2018 and January 2020, 192 patients (69.8% intermediate/poor-risk) were randomly assigned and received at least one dose of study drug. The incidence of grade 3-5 trAEs was significantly lower among participants receiving modified versus standard IPI (32.8% Conclusion: Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.
MeSH term(s)	Humans ; Nivolumab/therapeutic use ; Ipilimumab ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology
Chemical Substances	Nivolumab (31YO63LBSN) ; Ipilimumab
Language	English
Publishing date	2023-11-06
Publishing country	United States
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.23.00236
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.

Kamposioras, Konstantinos / Papaxoinis, George / Dawood, Mohamed / Appleyard, Jordan / Collinson, Fiona / Lamarca, Angela / Ahmad, Usman / Hubner, Richard A / Wright, Francesca / Pihlak, Rille / Damyanova, Iva / Razzaq, Bilal / Valle, Juan W / McNamara, Mairéad G / Anthoney, Alan

Acta oncologica (Stockholm, Sweden)

2022 Volume 61, Issue 5, Page(s) 583–590

Abstract: Background: Identifying pretreatment blood markers that distinguish prognostic groups of patients with advanced pancreatic ductal adenocarcinoma (PDAC) under first-line FOLFIRINOX chemotherapy has the potential to improve management of this condition. ... ...

Abstract	Background: Identifying pretreatment blood markers that distinguish prognostic groups of patients with advanced pancreatic ductal adenocarcinoma (PDAC) under first-line FOLFIRINOX chemotherapy has the potential to improve management of this condition. Aim of this study was to determine the prognostic utility of a range of pretreatment, inflammation-related, blood cell markers in this group of patients. Material and methods: Data from a training cohort were analyzed to identify potential pretreatment blood markers correlating to survival outcomes. The most informative markers were further analyzed in a validation cohort comprised patients from a geographically separate cancer center undergoing the same treatment. Results: A total of 138 consecutive patients receiving FOLFIRINOX chemotherapy between 2010 and 2019, constituted the training cohort. Neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), and platelet/lymphocyte ratio (PLR) as well as the systemic inflammatory response index (SIRI) and CA19.9 showed prognostic significance in addition to tumor stage. A pretreatment SIRI score cutoff of 2.35 differentiated between a poor prognostic group with median overall survival (mOS) 5.1 months and a better prognostic group, mOS 12.5 months. SIRI ≤/> 2.35 was predictive of mOS in patients with locally advanced and metastatic PDAC. SIRI was confirmed as a prognostic marker in a validation cohort of 67 patients with mOS of 13.4 months and 6.3 months for those with SIRI ≤ 2.35 and >2.35, respectively. Additional analysis revealed baseline SIRI as being prognostic within additional subgroups of patients in both cohorts. Conclusions: This large, retrospective, analysis of real-world patients receiving first-line FOLFIRINOX chemotherapy for advanced PDAC has identified the pretreatment blood SIRI as a strong prognostic marker for survival. This will allow better counseling of patients with regards to the benefits of treatment, improved stratification within clinical trials, and potentially identify groups of patients for novel therapy trials as first-line treatment.
MeSH term(s)	Adenocarcinoma/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers ; Fluorouracil ; Humans ; Inflammation/pathology ; Irinotecan ; Leucovorin ; Oxaliplatin ; Pancreatic Neoplasms/drug therapy ; Prognosis ; Retrospective Studies ; Pancreatic Neoplasms
Chemical Substances	Biomarkers ; folfirinox ; Oxaliplatin (04ZR38536J) ; Irinotecan (7673326042) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2022-04-07
Publishing country	England
Document type	Journal Article
ZDB-ID	896449-x
ISSN	1651-226X ; 0349-652X ; 0284-186X ; 1100-1704
ISSN (online)	1651-226X
ISSN	0349-652X ; 0284-186X ; 1100-1704
DOI	10.1080/0284186X.2022.2053198
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6348: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol.

Hull, Mark A / Ow, Pei Loo / Ruddock, Sharon / Brend, Tim / Smith, Alexandra F / Marshall, Helen / Song, Mingyang / Chan, Andrew T / Garrett, Wendy S / Yilmaz, Omer / Drew, David A / Collinson, Fiona / Cockbain, Andrew J / Jones, Robert / Loadman, Paul M / Hall, Peter S / Moriarty, Catherine / Cairns, David A / Toogood, Giles J

BMJ open

2023 Volume 13, Issue 11, Page(s) e077427

Abstract: Introduction: There remains an unmet need for safe and cost-effective adjunctive treatment of advanced colorectal cancer (CRC). The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) is safe, well-tolerated and has anti-inflammatory as well ... ...

Abstract	Introduction: There remains an unmet need for safe and cost-effective adjunctive treatment of advanced colorectal cancer (CRC). The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) is safe, well-tolerated and has anti-inflammatory as well as antineoplastic properties. A phase 2 randomised trial of preoperative EPA free fatty acid 2 g daily in patients undergoing surgery for CRC liver metastasis showed no difference in the primary endpoint (histological tumour proliferation index) compared with placebo. However, the trial demonstrated possible benefit for the prespecified exploratory endpoint of postoperative disease-free survival. Therefore, we tested the hypothesis that EPA treatment, started before liver resection surgery (and continued postoperatively), improves CRC outcomes in patients with CRC liver metastasis. Methods and analysis: The EPA for Metastasis Trial 2 trial is a randomised, double-blind, placebo-controlled, phase 3 trial of 4 g EPA ethyl ester (icosapent ethyl (IPE; Vascepa)) daily in patients undergoing liver resection surgery for CRC liver metastasis with curative intent. Trial treatment continues for a minimum of 2 years and maximum of 4 years, with 6 monthly assessments, including quality of life outcomes, as well as annual clinical record review after the trial intervention. The primary endpoint is CRC progression-free survival. Key secondary endpoints are overall survival, as well as the safety and tolerability of IPE. A minimum 388 participants are estimated to provide 247 CRC progression events during minimum 2-year follow-up, allowing detection of an HR of 0.7 in favour of IPE, with a power of 80% at the 5% (two sided) level of significance, assuming drop-out of 15%. Ethics and dissemination: Ethical and health research authority approval was obtained in January 2018. All data will be collected by 2025. Full trial results will be published in 2026. Secondary analyses of health economic data, biomarker studies and other translational work will be published subsequently. Trial registration number: NCT03428477.
MeSH term(s)	Humans ; Eicosapentaenoic Acid/therapeutic use ; Quality of Life ; Treatment Outcome ; Neoplasm Recurrence, Local/drug therapy ; Colorectal Neoplasms/pathology ; Double-Blind Method ; Liver Neoplasms/drug therapy ; Liver Neoplasms/surgery ; Liver Neoplasms/secondary ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic
Chemical Substances	Eicosapentaenoic Acid (AAN7QOV9EA)
Language	English
Publishing date	2023-11-29
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2023-077427
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: New therapeutic agents in ovarian cancer.

Collinson, Fiona / Jayson, Gordon

Current opinion in obstetrics & gynecology

2008 Volume 21, Issue 1, Page(s) 44–53

Abstract: Purpose of review: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed.: Recent ... ...

Abstract	Purpose of review: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. Recent findings: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. Summary: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.
MeSH term(s)	Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Bevacizumab ; Carboplatin/therapeutic use ; Drug Administration Routes ; ErbB Receptors/antagonists & inhibitors ; Female ; Humans ; Neovascularization, Pathologic/drug therapy ; Ovarian Neoplasms/blood supply ; Ovarian Neoplasms/drug therapy ; Paclitaxel/adverse effects ; Paclitaxel/therapeutic use ; Poly Adenosine Diphosphate Ribose/antagonists & inhibitors ; Protein Kinase Inhibitors/therapeutic use ; Proteins/antagonists & inhibitors ; Randomized Controlled Trials as Topic ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Protein Kinase Inhibitors ; Proteins ; Vascular Endothelial Growth Factor A ; poly(ADP)-ribosylated proteins ; Poly Adenosine Diphosphate Ribose (26656-46-2) ; Bevacizumab (2S9ZZM9Q9V) ; Carboplatin (BG3F62OND5) ; ErbB Receptors (EC 2.7.10.1) ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2008-12-18
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1049382-7
ISSN	1473-656X ; 1040-872X
ISSN (online)	1473-656X
ISSN	1040-872X
DOI	10.1097/GCO.0b013e32831ffe71
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3048: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.

Collinson, Fiona J / Seligmann, Jenny / Perren, Timothy J

Current oncology reports

2012 Volume 14, Issue 6, Page(s) 509–518

Abstract: Ovarian cancer is an important health concern worldwide. The majority of patients present with advanced disease, and despite initial chemosensitivity, most relapse and die from their disease. Better therapeutic options are urgently required. Maximal ... ...

Abstract	Ovarian cancer is an important health concern worldwide. The majority of patients present with advanced disease, and despite initial chemosensitivity, most relapse and die from their disease. Better therapeutic options are urgently required. Maximal surgical debulking in combination with platinum/taxane chemotherapy has been the standard of care in advanced ovarian cancer since the mid-1990s. Trials investigating the addition of a third chemotherapeutic agent have disappointingly failed to demonstrate benefit. Intra-peritoneal therapy demonstrated improvements in outcomes in some trials, but at the cost of increased toxicity and inconvenience. Encouragingly, prospective data has now demonstrated benefits with bevacizumab in both the first-line and relapsed settings; however, interpretation is complex, particularly considering recent data demonstrating non-inferiority of neo-adjuvant chemotherapy with delayed primary surgery, and other data demonstrating a substantial improvement in outcome as a result of first-line paclitaxel dose fractionation. This article reviews the recent advances in ovarian cancer treatment and discusses current management and key areas for future research.
MeSH term(s)	Angiogenesis Inhibitors/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bevacizumab ; Female ; Humans ; Meta-Analysis as Topic ; Neoadjuvant Therapy ; Neovascularization, Pathologic/pathology ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Bevacizumab (2S9ZZM9Q9V) ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2012-09-05
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-012-0274-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito